Skip to content
10-Q

Quarterly Report

Kiromic Biopharma, Inc.

0001437749-24-025818

← back to feed
Filed
Aug 9, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 7, 2024 1.55M sh
Capex Q2 2024 · Jun 30, 2024 $119K
Capex Q2 2024 · Jun 30, 2023 $0
Operating Cash Flow Q2 2024 · Jun 30, 2024 −$13.88M
Operating Cash Flow restated Q2 2024 · Jun 30, 2023 −$10.59M
Cash And Equivalents Q2 2024 · Jun 30, 2024 $4.05M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $3.2M
Cash And Equivalents restated Q2 2024 · Jun 30, 2023 $2.7M
Stockholders Equity Q2 2024 · Jun 30, 2024 −$5.17M
Stockholders Equity Q2 2024 · Mar 31, 2024 −$7.21M
Stockholders Equity Q2 2024 · Dec 31, 2023 −$9.12M
Stockholders Equity restated Q2 2024 · Jun 30, 2023 −$6.3M
Stockholders Equity restated Q2 2024 · Mar 31, 2023 −$8.14M
Stockholders Equity restated Q2 2024 · Dec 31, 2022 −$5.78M
Current Liabilities Q2 2024 · Jun 30, 2024 $17.06M
Current Liabilities Q2 2024 · Dec 31, 2023 $20.38M
Total Liabilities Q2 2024 · Jun 30, 2024 $17.63M
Total Liabilities Q2 2024 · Dec 31, 2023 $21.29M
Current Assets Q2 2024 · Jun 30, 2024 $6.03M
Current Assets Q2 2024 · Dec 31, 2023 $4.43M
Total Assets Q2 2024 · Jun 30, 2024 $12.46M
Total Assets Q2 2024 · Dec 31, 2023 $12.17M
Sga Expense Q2 2024 · Jun 30, 2024 $2.22M
Sga Expense Q2 2024 · Jun 30, 2024 $4.31M
Sga Expense restated Q2 2024 · Jun 30, 2023 $2.33M
Sga Expense restated Q2 2024 · Jun 30, 2023 $5.03M
Rd Expense Q2 2024 · Jun 30, 2024 $4.14M
Rd Expense Q2 2024 · Jun 30, 2024 $7.16M
Rd Expense restated Q2 2024 · Jun 30, 2023 $1.97M
Rd Expense restated Q2 2024 · Jun 30, 2023 $4.04M
Net Income Q2 2024 · Jun 30, 2024 −$6.83M
Net Income Q2 2024 · Jun 30, 2024 −$12.97M
Net Income Q2 2024 · Mar 31, 2024 −$6.15M
Net Income restated Q2 2024 · Jun 30, 2023 −$6.76M
Net Income restated Q2 2024 · Jun 30, 2023 −$12.06M
Net Income restated Q2 2024 · Mar 31, 2023 −$5.3M
Operating Income Q2 2024 · Jun 30, 2024 −$6.35M
Operating Income Q2 2024 · Jun 30, 2024 −$11.47M
Operating Income restated Q2 2024 · Jun 30, 2023 −$4.29M
Operating Income restated Q2 2024 · Jun 30, 2023 −$9.07M
Revenue Q2 2024 · Jun 30, 2024 $0